# Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

> **NCT06423326** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 36 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Adenocarcinoma
- Stage I Pancreatic Cancer AJCC v8
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Gemcitabine
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Nab-paclitaxel
- **PROCEDURE:** Pancreatic Surgical Procedure

## Key facts

- **NCT ID:** NCT06423326
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423326, "Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06423326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*